GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » EV-to-Revenue

Genor Biopharma Holdings (HKSE:06998) EV-to-Revenue : 1.06 (As of May. 29, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Genor Biopharma Holdings's enterprise value is HK$232.6 Mil. Genor Biopharma Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was HK$220.3 Mil. Therefore, Genor Biopharma Holdings's EV-to-Revenue for today is 1.06.

The historical rank and industry rank for Genor Biopharma Holdings's EV-to-Revenue or its related term are showing as below:

HKSE:06998' s EV-to-Revenue Range Over the Past 10 Years
Min: -246.48   Med: -57.79   Max: 909.37
Current: 1.06

During the past 7 years, the highest EV-to-Revenue of Genor Biopharma Holdings was 909.37. The lowest was -246.48. And the median was -57.79.

HKSE:06998's EV-to-Revenue is ranked better than
84.25% of 997 companies
in the Biotechnology industry
Industry Median: 7.47 vs HKSE:06998: 1.06

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-29), Genor Biopharma Holdings's stock price is HK$2.64. Genor Biopharma Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.43. Therefore, Genor Biopharma Holdings's PS Ratio for today is 6.18.


Genor Biopharma Holdings EV-to-Revenue Historical Data

The historical data trend for Genor Biopharma Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings EV-to-Revenue Chart

Genor Biopharma Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial 517.59 - -22.78 - -1.07

Genor Biopharma Holdings Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.78 - - - -1.07

Competitive Comparison of Genor Biopharma Holdings's EV-to-Revenue

For the Biotechnology subindustry, Genor Biopharma Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genor Biopharma Holdings's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Genor Biopharma Holdings's EV-to-Revenue falls into.


;
;

Genor Biopharma Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Genor Biopharma Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=232.636/220.314
=1.06

Genor Biopharma Holdings's current Enterprise Value is HK$232.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genor Biopharma Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was HK$220.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genor Biopharma Holdings  (HKSE:06998) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Genor Biopharma Holdings's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=2.64/0.427
=6.18

Genor Biopharma Holdings's share price for today is HK$2.64.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.43.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genor Biopharma Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Genor Biopharma Holdings Business Description

Traded in Other Exchanges
Address
690 Bibo Road, Room 501-02, Building 6, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
Executives
Forebright New Opportunities Fund, L.p. 2101 Beneficial owner
Forbright Global Limited 2201 Interest of corporation controlled by you
Fnof Gp Limited 2201 Interest of corporation controlled by you
Deg – Deutsche Investitions- Und Entwicklungsgesellschaft Mbh 2101 Beneficial owner
Hsg Growth V Holdco Q, Ltd. 2101 Beneficial owner
Hsg Holding Limited 2201 Interest of corporation controlled by you
Snp China Enterprises Limited 2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund Management I, L.p. 2201 Interest of corporation controlled by you
Shen Nan Peng 2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund I, L.p. 2101 Beneficial owner
Hongshan Capital Growth Fund V, L.p. 2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p. 2201 Interest of corporation controlled by you
Hongshan Capital Management I, L.p. 2201 Interest of corporation controlled by you
Hongshan Capital I, L.p. 2101 Beneficial owner
Ni Xin 2101 Beneficial owner

Genor Biopharma Holdings Headlines

No Headlines